Literature DB >> 7594678

Parvovirus B19 clearance from peripheral blood after acute infection.

M Musiani1, M Zerbini, G Gentilomi, M Plazzi, G Gallinella, S Venturoli.   

Abstract

The clearance of B19 parvovirus from peripheral blood was followed after acute infection to determine how long the virus is present in blood, even at low titer. The presence of B19 DNA in serum was investigated with dot blot hybridization during an epidemic. Fourteen patients positive for B19 DNA were followed for up to 1 year for its presence in samples taken monthly, using both dot blot hybridization and nested polymerase chain reaction (PCR). All patients examined showed medium to high viremic titers (detectable with hybridization assay) only at the beginning of observation; later the virus titer decreased and was detectable only by nested PCR. Of the 14 patients followed, 13 were positive for B19 DNA by nested PCR for 2-6 months; 1 patient showed a persistent infection associated with chronic arthritis and was positive for B19 DNA for 1 year without clearance of the virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594678     DOI: 10.1093/infdis/172.5.1360

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  22 in total

1.  Chronic hepatitis caused by persistent parvovirus B19 infection.

Authors:  Trine H Mogensen; Jens Magnus B Jensen; Stephen Hamilton-Dutoit; Carsten S Larsen
Journal:  BMC Infect Dis       Date:  2010-08-20       Impact factor: 3.090

2.  Detection of parvovirus B19 in skin biopsy, serum, and bone marrow of a patient with fever, rash, and polyarthritis followed by pneumonia, pericardial effusion, and hepatitis.

Authors:  S Nikkari; H Lappalainen; R Saario; K Lammintausta; P Kotilainen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-12       Impact factor: 3.267

3.  Comparative evaluation of virological and serological methods in prenatal diagnosis of parvovirus B19 fetal hydrops.

Authors:  M Zerbini; M Musiani; G Gentilomi; S Venturoli; G Gallinella; R Morandi
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

4.  Dot immunoperoxidase assay for detection of parvovirus B19 antigens in serum samples.

Authors:  G Gentilomi; M Musiani; M Zerbini; G Gallinella; S Venturoli; E Manaresi
Journal:  J Clin Microbiol       Date:  1997-06       Impact factor: 5.948

5.  Increased risk of parvovirus B19 infection in young adult cancer patients receiving multiple courses of chemotherapy.

Authors:  Sung-Hsin Kuo; Liang-In Lin; Chee-Jen Chang; Yun-Ru Liu; Kuo-Sin Lin; Ann-Lii Cheng
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Alphavirus-specific cytotoxic T lymphocytes recognize a cross-reactive epitope from the capsid protein and can eliminate virus from persistently infected macrophages.

Authors:  M L Linn; L Mateo; J Gardner; A Suhrbier
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  High-sensitivity PCR detection of parvovirus B19 in plasma.

Authors:  P Daly; A Corcoran; B P Mahon; S Doyle
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

8.  Bioportfolio: lifelong persistence of variant and prototypic erythrovirus DNA genomes in human tissue.

Authors:  Päivi Norja; Kati Hokynar; Leena-Maija Aaltonen; Renwei Chen; Annamari Ranki; Esa K Partio; Olli Kiviluoto; Irja Davidkin; Tomi Leivo; Anna Maria Eis-Hübinger; Beate Schneider; Hans-Peter Fischer; René Tolba; Olli Vapalahti; Antti Vaheri; Maria Söderlund-Venermo; Klaus Hedman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Quantification of parvovirus B19 DNA using COBAS AmpliPrep automated sample preparation and LightCycler real-time PCR.

Authors:  Stefan Schorling; Gunnar Schalasta; Gisela Enders; Michael Zauke
Journal:  J Mol Diagn       Date:  2004-02       Impact factor: 5.568

10.  Detection and differentiation of human parvovirus variants by commercial quantitative real-time PCR tests.

Authors:  Kati Hokynar; Päivi Norja; Harri Laitinen; Pekka Palomäki; Antoine Garbarg-Chenon; Annamari Ranki; Klaus Hedman; Maria Söderlund-Venermo
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.